Deniz, Çiğdem DamlaGürbilek, MehmetMehmet, Koç2020-01-182020-01-182018Deniz, Ç. D., Gürbilek, M., Koç, M. (2018). Prognostic value of interferon-gamma, interleukin-6, and tumor necrosis factor-alpha in the radiation response of patients diagnosed with locally advanced non-small-cell lung cancer and glioblastoma multiforme. Turkish Journal of Medical Sciences, 48, 1, 117-123.1300-01441303-6165https://dx.doi.org/10.3906/sag-1611-77https://app.trdizin.gov.tr/makale/TWprNU1UVXlNZz09/prognostic-value-of-interferon-gamma-interleukin-6-and-tumor-necrosis-factor-alpha-in-the-radiation-response-of-patients-diagnosed-with-locally-advanced-non-small-cell-lung-cancer-and-glioblastoma-multiformehttps://hdl.handle.net/20.500.12452/1874WOS:000425902900020PubMed ID:29479968Background/aim: This study aimed to investigate the effect of chemoradiotherapy (CRT) on interferon-gamma, interleukin-6(IL-6), and tumor necrosis factor-alpha, which are critical markers of the clinical radiation response of patients with locallyadvanced non-small-cell lung cancer (NSCLC) and glioblastoma multiforme (GBM).Materials and methods: Thirty patients who were treated with CRT and 20 healthy controls were prospectively evaluated. Circulatinglevels of cytokines were measured by enzyme-linked immunosorbent assay procedure. Post-CRT and pre-CRT levels were compared.Results: Post-CRT, TNF- and IFN- levels were significantly lower than pre-CRT levels in the NSCLC and GBM groups, respectively.The statistical analysis did not show any significant difference between the post- and pre-CRT IL-6 levels. However, the pre-CRT IL-6levels in the GBM group and post-CRT IL-6 levels in the NSCLC group were significantly higher than those of the control group.Conclusion: CRT affected TNF- levels in NSCLC and IFN- levels in GBM, with the levels of both decreasing significantly. The IL-6levels of the post-CRT NSCLC group were higher than those of the post-CRT GBM group. Irradiation-induced IL-6 may be responsiblefor tumor regrowth. Therefore, treatment with IL-6 inhibitors could be a potential therapeutic strategy for sensitizing NSCLC toirradiation in the clinic.eninfo:eu-repo/semantics/openAccessInterferon-gammaİnterleukin-6Tumor necrosis factor-alphaCancerRadiotherapyArticle48111712329479968Q3WOS:000425902900020Q410.3906/sag-1611-77